<DOC>
	<DOCNO>NCT00444912</DOCNO>
	<brief_summary>Participants non-Hodgkin lymphoma ( NHL ) Hodgkin disease ( HD ) assign one 2 arm base immunophenotype lymphoma . ( A ) Participants CD20 ( - ) lymphoma undergo mobilization granulocyte colony-stimulating factor ( G-CSF ) plerixafor . ( B ) Participants CD20 ( + ) lymphomas undergo mobilization rituximab , G-CSF , plerixafor . They receive weekly dose rituximab begin 1 week prior , continue 2 week , first dose G-CSF . Participants group receive G-CSF twice daily 4 day . In even Day 4 , dose plerixafor administer . Apheresis initiate next morning . Participants continue receive G-CSF twice daily receive evening dose plerixafor follow apheresis next morning total 4 aphereses ≥5*10^6 CD34+ cells/kg collect . Participants transplant monitored time polymorphonuclear leukocyte ( PMN ) , platelet ( PLT ) , lymphocyte engraftment . Follow-up assessment do 100 day , 6 12 month post-transplantation .</brief_summary>
	<brief_title>The Effect Rituximab Mobilization With AMD3100 ( Plerixafor ) Plus G-CSF Patients With Relapsed Refractory Non-Hodgkin Lymphoma ( NHL ) Hodgkin Disease ( HD )</brief_title>
	<detailed_description>This single-center , 2-arm , non-randomized , open-label study evaluate safety plerixafor use combination rituximab ( Rituxan® ) granulocyte colony-stimulating factor ( G-CSF ) patient relapse refractory Hodgkin disease ( HD ) non-Hodgkin lymphoma ( NHL ) . Participants assign one 2 arm base immunophenotype lymphoma . ( A ) Participants CD20 ( - ) lymphoma undergo mobilization G-CSF plerixafor . ( B ) Participants CD20 ( + ) lymphomas undergo mobilization rituximab , G-CSF , plerixafor . They receive weekly dose 375 mg/m2 rituximab intravenous ( iv ) infusion begin 1 week prior , continue 2 week , first dose G-CSF . Participants group receive 7.5 µg/kg G-CSF twice daily ( morning evening ) 4 day . In even ( approximately 10:00 pm ) Day 4 , dose plerixafor ( 240 µg/kg ) administer . Apheresis initiate next morning , approximately 10 11 hour plerixafor give . Participants continue receive G-CSF twice daily receive evening dose plerixafor follow apheresis next morning total 4 aphereses ≥5*10^6 CD34+ cells/kg collect . Participants adequate number autologous peripheral blood stem cell ( PBSCs ) collect apheresis admit study center administration high-dose chemotherapy autologous transplantation . After transplantation , time PMN , PLT , lymphocyte engraftment measure . Participants remain hospitalized achieve absolute granulocyte count &gt; 500/µl peripheral blood . Graft durability assess 100 day , 6 12 month post-transplantation . This study previously post AnorMED , Inc . In November 2006 , AnorMED , Inc. acquire Genzyme Corporation . Genzyme Corporation sponsor trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Inclusion Criteria ( abbreviated list ) : Histological diagnosis diffuse large cell lymphoma , Bcell , Tcell anaplastic histology ; peripheral Tcell lymphoma ; small noncleaved Burkittlike lymphoma ; Hodgkin disease . NOTE : Participants diagnose facility outside Emory University diagnosis confirm Emory University pathologists prior enrol study . Eligible autologous transplantation . History relapse lymphoma follow initial treatment anthracyclinecontaining regimen disease refractory progress initial therapy anthracyclinecontaining regimen . Immunophenotyping lymphoma time diagnosis relapse use flow cytometry immunohistochemistry . Presence clinically and/or radiologicallydocumented , measurable , and/or evaluable disease time relapse . Received 2 cycle salvage chemotherapy . Complete response ( i.e. , normal physical examination , lymph node , lymph node mass , bone marrow ) partial response ( i.e. , decrease ≧50 % size lymph node lymph node mass decrease size liver/spleen physical exam ) least one cycle salvage chemotherapy regimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Absolute granulocyte count ≧1.0*10^9/l . Platelet count ≧75*10^9/l . Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) ≦2.5 time upper limit normal ( ULN ) ≦5 time ULN liver involvement lymphoma . Life expectancy least 3 month . &gt; 4 week since last cycle chemotherapy . Patient recover acute toxic effect prior chemotherapy . Signed informed consent . Exclusion Criteria ( abbreviated list ) : A second active malignancy ( basal cell carcinoma skin ) . Uncontrolled central nervous system involvement lymphoma . Positive/history retroviral infection ( HIV , HTLV1 ) . Active infection require antibiotic plan lymphomarelated therapy . Previous treatment highdose chemotherapy cytokine mobilization hematopoietic progenitor cell transplantation . Continued evidence morphology flow cytometry bone marrow involvement least one cycle salvage chemotherapy . ≥3 cycle salvage chemotherapy follow documentation lymphoma relapse disease progression . ( In patient CD20 ( + ) lymphoma ) History severe hypersensitivity reaction rituximab . Positive pregnancy test female patient . Lactating female patient . Previously receive experimental therapy within 4 week enrol protocol currently enrol another experimental protocol GCSF Mobilization Phase . Creatinine &gt; 1.5 time ULN . Bilirubin &gt; 1.5 time ULN . Ejection fraction &lt; 45 % . Diffusion capacity lung carbon monoxide ( DLCO ) &lt; 50 % . Patients childbearing potential unwilling implement adequate birth control . A comorbid condition render patient high risk treatment complication . Residual acute medical condition result prior chemotherapy . Documented history ventricular arrhythmias last 3 year . Fever ( temperature &gt; 38 °C/100.4 °F ) . Actual body weight exceeds 175 % ideal body weight . Participants deterioration clinical status laboratory parameter time enrolment transplant ( long meet entry criterion ) may remove study discretion treat physician , principal investigator , sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>AMD3100</keyword>
	<keyword>stem cell mobilization</keyword>
	<keyword>autologous transplant</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Hodgkin Disease</keyword>
</DOC>